Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, Vaxcyte, Inc. (PCVX) has a Wall Street consensus price target of $83.00, based on estimates from 11 covering analysts. With the stock currently trading at $61.74, this represents a potential upside of +34.4%. The company has a market capitalization of $8.09B.
Analyst price targets range from a low of $77.00 to a high of $89.00, representing a 14% spread in expectations. The median target of $83.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 11 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PCVX trades at a trailing P/E of -11.0x. Analysts expect EPS to grow -24.0% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how PCVX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for PCVX is $83, representing 34.4% upside from the current price of $61.74. With 11 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
PCVX has a consensus rating of "Buy" based on 11 Wall Street analysts. The rating breakdown is predominantly bullish, with 11 Buy/Strong Buy ratings. The consensus 12-month price target of $83 implies 34.4% upside from current levels.
PCVX's current price is $61.74 with a consensus target of $83 (34.4% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $89 for PCVX, while the most conservative target is $77. The consensus of $83 represents the median expectation. These targets typically reflect 12-month expectations.
PCVX is moderately covered, with 11 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PCVX stock forecast based on 11 Wall Street analysts shows a consensus price target of $83, with estimates ranging from $77 (bear case) to $89 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on PCVX, with a "Buy" consensus rating and $83 price target (34.4% upside). 11 of 11 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PCVX analyst price targets range from $77 to $89, a 14% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $83 consensus represents the middle ground.